The effect of sorbinil treatment on red cell sorbitol levels and clinical and electrophysiological parameters of diabetic neuropathy
Summary A randomized placebo-controlled double-blind cross-over study was conducted in order to examine the effect of an aldose reductase inhibitor, sorbinil (100 mg daily for 4 weeks), on red cell sorbitol concentration and clinical and electrophysiological parameters of diabetic neuropathy. A tota...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1986 |
|---|
| Umfang: |
4 |
|---|
| Reproduktion: |
Springer Online Journal Archives 1860-2002 |
|---|---|
| Übergeordnetes Werk: |
in: Journal of neurology - 1891, 233(1986) vom: März, Seite 174-177 |
| Übergeordnetes Werk: |
volume:233 ; year:1986 ; month:03 ; pages:174-177 ; extent:4 |
| Links: |
|---|
| Katalog-ID: |
NLEJ20899405X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ20899405X | ||
| 003 | DE-627 | ||
| 005 | 20210707031329.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 070529s1986 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)NLEJ20899405X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a The effect of sorbinil treatment on red cell sorbitol levels and clinical and electrophysiological parameters of diabetic neuropathy |
| 264 | 1 | |c 1986 | |
| 300 | |a 4 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Summary A randomized placebo-controlled double-blind cross-over study was conducted in order to examine the effect of an aldose reductase inhibitor, sorbinil (100 mg daily for 4 weeks), on red cell sorbitol concentration and clinical and electrophysiological parameters of diabetic neuropathy. A total of 31 diabetic patients with either clinically or electrophysiologically verified diabetic neuropathy were studied. Red cell sorbitol levels decreased significantly to the levels reported in non-diabetic subjects, but there were no significant changes in symptoms, signs, vibration perception thresholds or nerve conduction variables. One patient had transient skin rash, fever, myalgia and leucopenia, but no other significant adverse effects were found. | ||
| 533 | |f Springer Online Journal Archives 1860-2002 | ||
| 700 | 1 | |a Lehtinen, J. M. |4 oth | |
| 700 | 1 | |a Hyvönen, S. K. |4 oth | |
| 700 | 1 | |a Uusitupa, M. |4 oth | |
| 700 | 1 | |a Puhakainen, E. |4 oth | |
| 700 | 1 | |a Halonen, T. |4 oth | |
| 700 | 1 | |a Kilpeläinen, H. |4 oth | |
| 773 | 0 | 8 | |i in |t Journal of neurology |d 1891 |g 233(1986) vom: März, Seite 174-177 |w (DE-627)NLEJ188985883 |w (DE-600)1421299-7 |x 1432-1459 |7 nnns |
| 773 | 1 | 8 | |g volume:233 |g year:1986 |g month:03 |g pages:174-177 |g extent:4 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/BF00314428 |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-SOJ | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 233 |j 1986 |c 3 |h 174-177 |g 4 | ||
| matchkey_str |
article:14321459:1986----::hefcosriitetetneclsriolvladlnclneetohsooia |
|---|---|
| hierarchy_sort_str |
1986 |
| publishDate |
1986 |
| allfields |
(DE-627)NLEJ20899405X DE-627 ger DE-627 rakwb eng The effect of sorbinil treatment on red cell sorbitol levels and clinical and electrophysiological parameters of diabetic neuropathy 1986 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary A randomized placebo-controlled double-blind cross-over study was conducted in order to examine the effect of an aldose reductase inhibitor, sorbinil (100 mg daily for 4 weeks), on red cell sorbitol concentration and clinical and electrophysiological parameters of diabetic neuropathy. A total of 31 diabetic patients with either clinically or electrophysiologically verified diabetic neuropathy were studied. Red cell sorbitol levels decreased significantly to the levels reported in non-diabetic subjects, but there were no significant changes in symptoms, signs, vibration perception thresholds or nerve conduction variables. One patient had transient skin rash, fever, myalgia and leucopenia, but no other significant adverse effects were found. Springer Online Journal Archives 1860-2002 Lehtinen, J. M. oth Hyvönen, S. K. oth Uusitupa, M. oth Puhakainen, E. oth Halonen, T. oth Kilpeläinen, H. oth in Journal of neurology 1891 233(1986) vom: März, Seite 174-177 (DE-627)NLEJ188985883 (DE-600)1421299-7 1432-1459 nnns volume:233 year:1986 month:03 pages:174-177 extent:4 http://dx.doi.org/10.1007/BF00314428 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 233 1986 3 174-177 4 |
| spelling |
(DE-627)NLEJ20899405X DE-627 ger DE-627 rakwb eng The effect of sorbinil treatment on red cell sorbitol levels and clinical and electrophysiological parameters of diabetic neuropathy 1986 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary A randomized placebo-controlled double-blind cross-over study was conducted in order to examine the effect of an aldose reductase inhibitor, sorbinil (100 mg daily for 4 weeks), on red cell sorbitol concentration and clinical and electrophysiological parameters of diabetic neuropathy. A total of 31 diabetic patients with either clinically or electrophysiologically verified diabetic neuropathy were studied. Red cell sorbitol levels decreased significantly to the levels reported in non-diabetic subjects, but there were no significant changes in symptoms, signs, vibration perception thresholds or nerve conduction variables. One patient had transient skin rash, fever, myalgia and leucopenia, but no other significant adverse effects were found. Springer Online Journal Archives 1860-2002 Lehtinen, J. M. oth Hyvönen, S. K. oth Uusitupa, M. oth Puhakainen, E. oth Halonen, T. oth Kilpeläinen, H. oth in Journal of neurology 1891 233(1986) vom: März, Seite 174-177 (DE-627)NLEJ188985883 (DE-600)1421299-7 1432-1459 nnns volume:233 year:1986 month:03 pages:174-177 extent:4 http://dx.doi.org/10.1007/BF00314428 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 233 1986 3 174-177 4 |
| allfields_unstemmed |
(DE-627)NLEJ20899405X DE-627 ger DE-627 rakwb eng The effect of sorbinil treatment on red cell sorbitol levels and clinical and electrophysiological parameters of diabetic neuropathy 1986 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary A randomized placebo-controlled double-blind cross-over study was conducted in order to examine the effect of an aldose reductase inhibitor, sorbinil (100 mg daily for 4 weeks), on red cell sorbitol concentration and clinical and electrophysiological parameters of diabetic neuropathy. A total of 31 diabetic patients with either clinically or electrophysiologically verified diabetic neuropathy were studied. Red cell sorbitol levels decreased significantly to the levels reported in non-diabetic subjects, but there were no significant changes in symptoms, signs, vibration perception thresholds or nerve conduction variables. One patient had transient skin rash, fever, myalgia and leucopenia, but no other significant adverse effects were found. Springer Online Journal Archives 1860-2002 Lehtinen, J. M. oth Hyvönen, S. K. oth Uusitupa, M. oth Puhakainen, E. oth Halonen, T. oth Kilpeläinen, H. oth in Journal of neurology 1891 233(1986) vom: März, Seite 174-177 (DE-627)NLEJ188985883 (DE-600)1421299-7 1432-1459 nnns volume:233 year:1986 month:03 pages:174-177 extent:4 http://dx.doi.org/10.1007/BF00314428 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 233 1986 3 174-177 4 |
| allfieldsGer |
(DE-627)NLEJ20899405X DE-627 ger DE-627 rakwb eng The effect of sorbinil treatment on red cell sorbitol levels and clinical and electrophysiological parameters of diabetic neuropathy 1986 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary A randomized placebo-controlled double-blind cross-over study was conducted in order to examine the effect of an aldose reductase inhibitor, sorbinil (100 mg daily for 4 weeks), on red cell sorbitol concentration and clinical and electrophysiological parameters of diabetic neuropathy. A total of 31 diabetic patients with either clinically or electrophysiologically verified diabetic neuropathy were studied. Red cell sorbitol levels decreased significantly to the levels reported in non-diabetic subjects, but there were no significant changes in symptoms, signs, vibration perception thresholds or nerve conduction variables. One patient had transient skin rash, fever, myalgia and leucopenia, but no other significant adverse effects were found. Springer Online Journal Archives 1860-2002 Lehtinen, J. M. oth Hyvönen, S. K. oth Uusitupa, M. oth Puhakainen, E. oth Halonen, T. oth Kilpeläinen, H. oth in Journal of neurology 1891 233(1986) vom: März, Seite 174-177 (DE-627)NLEJ188985883 (DE-600)1421299-7 1432-1459 nnns volume:233 year:1986 month:03 pages:174-177 extent:4 http://dx.doi.org/10.1007/BF00314428 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 233 1986 3 174-177 4 |
| allfieldsSound |
(DE-627)NLEJ20899405X DE-627 ger DE-627 rakwb eng The effect of sorbinil treatment on red cell sorbitol levels and clinical and electrophysiological parameters of diabetic neuropathy 1986 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary A randomized placebo-controlled double-blind cross-over study was conducted in order to examine the effect of an aldose reductase inhibitor, sorbinil (100 mg daily for 4 weeks), on red cell sorbitol concentration and clinical and electrophysiological parameters of diabetic neuropathy. A total of 31 diabetic patients with either clinically or electrophysiologically verified diabetic neuropathy were studied. Red cell sorbitol levels decreased significantly to the levels reported in non-diabetic subjects, but there were no significant changes in symptoms, signs, vibration perception thresholds or nerve conduction variables. One patient had transient skin rash, fever, myalgia and leucopenia, but no other significant adverse effects were found. Springer Online Journal Archives 1860-2002 Lehtinen, J. M. oth Hyvönen, S. K. oth Uusitupa, M. oth Puhakainen, E. oth Halonen, T. oth Kilpeläinen, H. oth in Journal of neurology 1891 233(1986) vom: März, Seite 174-177 (DE-627)NLEJ188985883 (DE-600)1421299-7 1432-1459 nnns volume:233 year:1986 month:03 pages:174-177 extent:4 http://dx.doi.org/10.1007/BF00314428 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 233 1986 3 174-177 4 |
| language |
English |
| source |
in Journal of neurology 233(1986) vom: März, Seite 174-177 volume:233 year:1986 month:03 pages:174-177 extent:4 |
| sourceStr |
in Journal of neurology 233(1986) vom: März, Seite 174-177 volume:233 year:1986 month:03 pages:174-177 extent:4 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| isfreeaccess_bool |
false |
| container_title |
Journal of neurology |
| authorswithroles_txt_mv |
Lehtinen, J. M. @@oth@@ Hyvönen, S. K. @@oth@@ Uusitupa, M. @@oth@@ Puhakainen, E. @@oth@@ Halonen, T. @@oth@@ Kilpeläinen, H. @@oth@@ |
| publishDateDaySort_date |
1986-03-01T00:00:00Z |
| hierarchy_top_id |
NLEJ188985883 |
| id |
NLEJ20899405X |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ20899405X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20210707031329.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070529s1986 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ20899405X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">The effect of sorbinil treatment on red cell sorbitol levels and clinical and electrophysiological parameters of diabetic neuropathy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1986</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">4</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary A randomized placebo-controlled double-blind cross-over study was conducted in order to examine the effect of an aldose reductase inhibitor, sorbinil (100 mg daily for 4 weeks), on red cell sorbitol concentration and clinical and electrophysiological parameters of diabetic neuropathy. A total of 31 diabetic patients with either clinically or electrophysiologically verified diabetic neuropathy were studied. Red cell sorbitol levels decreased significantly to the levels reported in non-diabetic subjects, but there were no significant changes in symptoms, signs, vibration perception thresholds or nerve conduction variables. One patient had transient skin rash, fever, myalgia and leucopenia, but no other significant adverse effects were found.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lehtinen, J. M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hyvönen, S. K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Uusitupa, M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Puhakainen, E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Halonen, T.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kilpeläinen, H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Journal of neurology</subfield><subfield code="d">1891</subfield><subfield code="g">233(1986) vom: März, Seite 174-177</subfield><subfield code="w">(DE-627)NLEJ188985883</subfield><subfield code="w">(DE-600)1421299-7</subfield><subfield code="x">1432-1459</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:233</subfield><subfield code="g">year:1986</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:174-177</subfield><subfield code="g">extent:4</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF00314428</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">233</subfield><subfield code="j">1986</subfield><subfield code="c">3</subfield><subfield code="h">174-177</subfield><subfield code="g">4</subfield></datafield></record></collection>
|
| series2 |
Springer Online Journal Archives 1860-2002 |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ188985883 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| collection |
NL |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1432-1459 |
| topic_title |
The effect of sorbinil treatment on red cell sorbitol levels and clinical and electrophysiological parameters of diabetic neuropathy |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
j m l jm jml s k h sk skh m u mu e p ep t h th h k hk |
| hierarchy_parent_title |
Journal of neurology |
| hierarchy_parent_id |
NLEJ188985883 |
| hierarchy_top_title |
Journal of neurology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ188985883 (DE-600)1421299-7 |
| title |
The effect of sorbinil treatment on red cell sorbitol levels and clinical and electrophysiological parameters of diabetic neuropathy |
| spellingShingle |
The effect of sorbinil treatment on red cell sorbitol levels and clinical and electrophysiological parameters of diabetic neuropathy |
| ctrlnum |
(DE-627)NLEJ20899405X |
| title_full |
The effect of sorbinil treatment on red cell sorbitol levels and clinical and electrophysiological parameters of diabetic neuropathy |
| journal |
Journal of neurology |
| journalStr |
Journal of neurology |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
1986 |
| contenttype_str_mv |
zzz |
| container_start_page |
174 |
| container_volume |
233 |
| physical |
4 |
| format_se |
Elektronische Aufsätze |
| title_sort |
the effect of sorbinil treatment on red cell sorbitol levels and clinical and electrophysiological parameters of diabetic neuropathy |
| title_auth |
The effect of sorbinil treatment on red cell sorbitol levels and clinical and electrophysiological parameters of diabetic neuropathy |
| abstract |
Summary A randomized placebo-controlled double-blind cross-over study was conducted in order to examine the effect of an aldose reductase inhibitor, sorbinil (100 mg daily for 4 weeks), on red cell sorbitol concentration and clinical and electrophysiological parameters of diabetic neuropathy. A total of 31 diabetic patients with either clinically or electrophysiologically verified diabetic neuropathy were studied. Red cell sorbitol levels decreased significantly to the levels reported in non-diabetic subjects, but there were no significant changes in symptoms, signs, vibration perception thresholds or nerve conduction variables. One patient had transient skin rash, fever, myalgia and leucopenia, but no other significant adverse effects were found. |
| abstractGer |
Summary A randomized placebo-controlled double-blind cross-over study was conducted in order to examine the effect of an aldose reductase inhibitor, sorbinil (100 mg daily for 4 weeks), on red cell sorbitol concentration and clinical and electrophysiological parameters of diabetic neuropathy. A total of 31 diabetic patients with either clinically or electrophysiologically verified diabetic neuropathy were studied. Red cell sorbitol levels decreased significantly to the levels reported in non-diabetic subjects, but there were no significant changes in symptoms, signs, vibration perception thresholds or nerve conduction variables. One patient had transient skin rash, fever, myalgia and leucopenia, but no other significant adverse effects were found. |
| abstract_unstemmed |
Summary A randomized placebo-controlled double-blind cross-over study was conducted in order to examine the effect of an aldose reductase inhibitor, sorbinil (100 mg daily for 4 weeks), on red cell sorbitol concentration and clinical and electrophysiological parameters of diabetic neuropathy. A total of 31 diabetic patients with either clinically or electrophysiologically verified diabetic neuropathy were studied. Red cell sorbitol levels decreased significantly to the levels reported in non-diabetic subjects, but there were no significant changes in symptoms, signs, vibration perception thresholds or nerve conduction variables. One patient had transient skin rash, fever, myalgia and leucopenia, but no other significant adverse effects were found. |
| collection_details |
GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE |
| title_short |
The effect of sorbinil treatment on red cell sorbitol levels and clinical and electrophysiological parameters of diabetic neuropathy |
| url |
http://dx.doi.org/10.1007/BF00314428 |
| remote_bool |
true |
| author2 |
Lehtinen, J. M. Hyvönen, S. K. Uusitupa, M. Puhakainen, E. Halonen, T. Kilpeläinen, H. |
| author2Str |
Lehtinen, J. M. Hyvönen, S. K. Uusitupa, M. Puhakainen, E. Halonen, T. Kilpeläinen, H. |
| ppnlink |
NLEJ188985883 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth |
| up_date |
2024-07-05T22:43:50.982Z |
| _version_ |
1803780810060333056 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ20899405X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20210707031329.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070529s1986 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ20899405X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">The effect of sorbinil treatment on red cell sorbitol levels and clinical and electrophysiological parameters of diabetic neuropathy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1986</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">4</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary A randomized placebo-controlled double-blind cross-over study was conducted in order to examine the effect of an aldose reductase inhibitor, sorbinil (100 mg daily for 4 weeks), on red cell sorbitol concentration and clinical and electrophysiological parameters of diabetic neuropathy. A total of 31 diabetic patients with either clinically or electrophysiologically verified diabetic neuropathy were studied. Red cell sorbitol levels decreased significantly to the levels reported in non-diabetic subjects, but there were no significant changes in symptoms, signs, vibration perception thresholds or nerve conduction variables. One patient had transient skin rash, fever, myalgia and leucopenia, but no other significant adverse effects were found.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lehtinen, J. M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hyvönen, S. K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Uusitupa, M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Puhakainen, E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Halonen, T.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kilpeläinen, H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Journal of neurology</subfield><subfield code="d">1891</subfield><subfield code="g">233(1986) vom: März, Seite 174-177</subfield><subfield code="w">(DE-627)NLEJ188985883</subfield><subfield code="w">(DE-600)1421299-7</subfield><subfield code="x">1432-1459</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:233</subfield><subfield code="g">year:1986</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:174-177</subfield><subfield code="g">extent:4</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF00314428</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">233</subfield><subfield code="j">1986</subfield><subfield code="c">3</subfield><subfield code="h">174-177</subfield><subfield code="g">4</subfield></datafield></record></collection>
|
| score |
7.4004383 |